SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network metaanalysis of randomised controlled trials
Semaglutide attenuates seizure severity and ameliorates cognitive dysfunction by blocking the NLR family pyrin domain containing 3 inflammasome in pentylenetetrazolekindled mice
SGLT-2 inhibitors and GLP-1RA, should be the preferred treatment for patients with type 2 diabetes and cardiorenal diseases after metformin
Eli Lilly has also released competing GLP-1 drugs in the form of Mounjaro (tirzepatide), approved for diabetes treatment in 2022, and a weight loss version of the drug was approved by the FDA last year, which is marketed under the brand name Zepbound
However, the agencies analyses at the time were hindered by the small number of reported instances of suicidal thoughts and behaviors, resulting in what the FDA on Monday called considerable uncertainty in the risk estimate. For more clarity on the matter, the agency conducted a meta-analysis of different GLP-1 trials, encompassing more than 90 studies and nearly 108,000 patients
